Constellation Pharmaceuticals, Inc.
https://www.constellationpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Constellation Pharmaceuticals, Inc.
MorphoSys May Be One To Watch at J.P. Morgan
Excitement continues to grow around pelabresib after the presentation of promising data for the German group’s myelofibrosis drug.
MorphoSys Keeps The Faith Despite Mixed Data For Myelofibrosis Combo
The jury is out on whether regulators have seen enough to approve pelabresib.
MorphoSys Confident Of A Win Over AbbVie In Myelofibrosis
Sales of the lymphoma drug Monjuvi continue to underwhelm but MorphoSys believes that its investigational BET inhibitor, pelabresib, can become a standard of care for the rare bone marrow disease myelofibrosis.
Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice